Shanghai Zhangjiang Kechuang investment is hot, and the stroke treatment field has received $150 million in financing

Solutions for ischemic cerebrovascular disease

Globally, stroke is the cause of death after cardiovascular disease, and China's stroke incidence is the highest in the world. In the past 30 years, the incidence of stroke in China has risen sharply and shown a trend of rejuvenation. As the construction of stroke centers in China enters the fast lane, the clinical demand for neurointerventional products is becoming increasingly urgent and diverse. On November 11, Minimally Invasive Brain Sciences, a subsidiary of Minimally Invasive Medical Science Co., Ltd. focusing on innovative treatment solutions for cerebrovascular diseases, successfully completed the formal signing of the US$150 million financing agreement as planned.

In recent years, shanghai Zhangjiang science and technology innovation park investment hotspots continue, micro-invasive medical is frequently optimistic about investors, subsidiaries have been favored by the market for many times. The financing introduced a number of well-known strategic investors, including CICC Capital, Huayi Capital, Bower Capital, Runkun Tianlu and Tongxin Investment, and Beilin Capital, which previously subscribed to the US$70 million convertible bond of MicroPort Brain Science, carried out equity conversion and follow-up investment in this round.

Minimally invasive brain science originated from minimally invasive shentong medical technology (Shanghai) Co., Ltd. established in 2012. As one of the earliest medical device companies in China to enter the field of neurointerventional intervention, Since its inception, Shentong Medical has developed and industrialized the first cerebrovascular stent in the field of neurointervention in China, APOLLO intracranial arterial stent system, the world's first intracranial lamination stent WILLIS intracranial lamination stent system, and the first blood flow guidance device Tubridge vascular reconstruction device in China, and other 8 self-developed three types of medical device products, with the most complete stroke intervention product line among domestic enterprises.

In the field of treatment of ischemic cerebrovascular disease, the APOLLO intracranial arterial stent system can be used to treat symptomatic intracranial atherosclerotic stenosis, and is the first dedicated intracranial stenosis stent in China. The Bridge vertebral rapamycin-targeted elution stent system uses a unique drug-loading design that allows for more precise drug release, significantly reduces intrastentercular restenosis, and reduces thrombotic events.

In the field of hemorrhagic stroke treatment, PSC has both the Tubridge vascular reconstruction device, which can be used to treat large and huge intracranial aneurysms, and the WILLIS intracranial mullion stent system for the treatment of intracranial arterial wall defect diseases. With the approval of the NUMEN spring coil embolization system and the NUMENFR relief controller in China in 2020, the hemorrhagic stroke product line of MiTAC is more complete. At present, NUMEN and NUMENFR have obtained CE certification from the European Union, the US Food and Drug Administration (FDA) and the Korean Food and Drug Safety Department (MFDS) for marketing, and completed the first overseas implant.

In terms of the channel auxiliary product line, MiTAC also has product layouts such as U-track intracranial support catheter system and Fastrack microcatheter system. Up to now, The products of MiTAC have covered 31 provinces and cities in China, entered about 2,000 hospitals, and treated a total of about 100,000 critically ill patients, and many of the company's products have obtained overseas registration certificates, which will improve or reshape the lives of more patients in future clinical applications.

After nearly 10 years of development, Shentong Medical has a talent team that is good at mining clinical pain points and outstanding innovation and research and development capabilities, and has more than 100 authorized patents at home and abroad.

In May 2021, Minimally Invasive Brain Science strategically invested in the Israeli company RapidMedical and became its largest shareholder, forming a more complete and diversified portfolio of out-of-body and ischemic products to promote the application of products in the global market; among them, RapidMedical's flagship product, tigertriever stent type embolic device, has also passed the application for special review of innovative medical devices by the State Drug Administration (NMPA) and entered the "green channel" of the special review process.

Bloomberg, Chairman of the Executive Committee of MicroPort Greater China, Chief Marketing Officer and Chairman of MicroPort Brain Science, said: "This round of financing has introduced several well-known strategic investors in China, making the shareholder structure and governance of MicroPort Brain Science more modern and professional, and multi-party resources to help MicroPort Brain Science accelerate the process of global development and jointly strive to promote the development of the neurointervention industry. ”

Author: Tang Wenjia

Editor: Tang Wenjia

Image source: Respondent